Announced Date: 2025-10-16 (October 16, 2025)
Licensor (Seller): Pregene Biopharma (China)
Licensee (Buyer): KitePharma (Gliead)
.
Asset Modality: In vivo CAR-T
Potential Indication:
Current Stage:
.
Scope of Authority:
Global
.
Payment Detail:
Pregene Biopharma will receive:
an upfront payment of US$120 million,
up to US$ 1.52 billion milestone payments,
royalties on potential future product sales.
.
Link:
18583428438544dda9b08acf1724282a.pdf (neeq.com.cn)
普瑞金（Pregene）与Kite达成战略合作 Pregene and Kite Entered into Strategic Collaboration-普瑞金
.
Note:
Chinese Name of Pregene Biopharma, 普瑞金生物
